Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery. [electronic resource]
Producer: 20150817Description: 1539-46.e1 p. digitalISSN:- 1097-685X
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biomarkers, Tumor -- analysis
- Chemotherapy, Adjuvant
- DNA-Binding Proteins -- analysis
- Deoxycytidine -- administration & dosage
- Disease Progression
- Disease-Free Survival
- Endonucleases -- analysis
- Female
- Glutamates -- administration & dosage
- Guanine -- administration & dosage
- Humans
- Immunohistochemistry
- Kaplan-Meier Estimate
- Lung Neoplasms -- enzymology
- Male
- Mesothelioma -- enzymology
- Mesothelioma, Malignant
- Middle Aged
- Multivariate Analysis
- Neoadjuvant Therapy
- Neoplasm Recurrence, Local
- Neoplasm Staging
- Pemetrexed
- Platinum Compounds -- administration & dosage
- Pleural Neoplasms -- enzymology
- Pneumonectomy
- Predictive Value of Tests
- Proportional Hazards Models
- Ribonucleoside Diphosphate Reductase
- Risk Factors
- Time Factors
- Tissue Array Analysis
- Treatment Outcome
- Tumor Suppressor Proteins -- analysis
- Gemcitabine
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.